Guardian Pharmacy Services (NYSE:GRDN) Cut to Hold at Wall Street Zen

Wall Street Zen cut shares of Guardian Pharmacy Services (NYSE:GRDN - Free Report) from a buy rating to a hold rating in a research note published on Saturday morning.

A number of other research firms also recently issued reports on GRDN. Raymond James set a $28.00 price objective on shares of Guardian Pharmacy Services and gave the stock an "outperform" rating in a report on Wednesday, May 14th. Truist Financial reiterated a "buy" rating and set a $28.00 target price (up from $25.00) on shares of Guardian Pharmacy Services in a research note on Monday, May 19th.

Guardian Pharmacy Services Stock Performance

Shares of GRDN stock traded down $0.08 during trading hours on Friday, hitting $21.37. 147,797 shares of the company were exchanged, compared to its average volume of 166,400. Guardian Pharmacy Services has a fifty-two week low of $14.16 and a fifty-two week high of $26.91. The company has a 50 day simple moving average of $23.14 and a two-hundred day simple moving average of $22.00.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported $0.21 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.01). The company had revenue of $329.31 million for the quarter, compared to analyst estimates of $321.21 million. On average, equities analysts forecast that Guardian Pharmacy Services will post 0.87 earnings per share for the current year.

Insider Activity at Guardian Pharmacy Services

In other news, insider Kendall Forbes sold 64,991 shares of the company's stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $20.16, for a total transaction of $1,310,218.56. Following the sale, the insider now directly owns 203,906 shares in the company, valued at $4,110,744.96. This represents a 24.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director William E. Bindley sold 651,454 shares of the company's stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $20.16, for a total value of $13,133,312.64. Following the sale, the director now owns 1,939,817 shares in the company, valued at approximately $39,106,710.72. This represents a 25.14% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,344,912 shares of company stock worth $228,713,426. Company insiders own 63.71% of the company's stock.

Institutional Investors Weigh In On Guardian Pharmacy Services

Hedge funds and other institutional investors have recently modified their holdings of the stock. Woodline Partners LP grew its holdings in shares of Guardian Pharmacy Services by 1.5% during the first quarter. Woodline Partners LP now owns 421,203 shares of the company's stock worth $8,955,000 after purchasing an additional 6,083 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Guardian Pharmacy Services during the first quarter worth about $233,000. Wellington Management Group LLP grew its holdings in shares of Guardian Pharmacy Services by 14.2% during the first quarter. Wellington Management Group LLP now owns 464,924 shares of the company's stock worth $9,884,000 after purchasing an additional 57,924 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Guardian Pharmacy Services by 23.4% in the first quarter. Russell Investments Group Ltd. now owns 90,401 shares of the company's stock worth $1,922,000 after buying an additional 17,160 shares in the last quarter. Finally, Premier Fund Managers Ltd purchased a new stake in Guardian Pharmacy Services in the first quarter worth approximately $435,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes.